Jassem J, Karnicka-Młodkowska H, Drozd-Lula M, Wiatr E, Słupek A, Marzinek M, Krawczyk K, Lisowska B, Tyrakowska J, Moś-Antkowiak R
Pneumonol Pol. 1989 Oct-Dec;57(10-12):496-503.
The analysis of clinical determinants of long-term survival in small cell lung cancer was investigated in consecutive series of 469 patients included in prospective multicenter clinical trials from 1981 to 1985. Forty eight patients (19.2%) were alive after 2 years from initiation of therapy and among them 27 (5.8%) were disease free. The most important clinical determinants of long-term survival were: extent of disease, performance status and sex. 38 out of 243 patients with limited disease (15.6%) survived for 2 years or more as well as 10 out of 226 patients with extensive disease (4.4%, p less than 0.001), 33 out of 237 patients with WHO performance status 0 and 1 (13.9%), and 15 out of 232 patients with performance status from 2 to 4 (6.4%, p less than 0.01), 29 out of 229 (12.2%) with absence of weight loss before therapy and 19 out of 240 (7.9%) with weight loss (N.S.), 32 out of 392 males (8.2%) and 16 out of 77 females (20.7%, p less than 0.01). Out of 27 disease-free survivors 21 are alive with no sign of malignancy after 3.5 to 7 years from initiation of therapy. Ten patients out of 229 followed up for a minimum 5 years after inclusion to the studies survived this period with no signs of disease. This study confirms the possible curability of small cell lung cancer, especially in patients with favorable prognostic characteristic.
对1981年至1985年前瞻性多中心临床试验纳入的469例连续病例进行了小细胞肺癌长期生存临床决定因素的分析。48例患者（19.2%）在治疗开始后2年存活，其中27例（5.8%）无疾病。长期生存的最重要临床决定因素为：疾病范围、体能状态和性别。243例局限性疾病患者中有38例（15.6%）存活2年或更长时间，226例广泛性疾病患者中有10例（4.4%，p<0.001）；237例WHO体能状态为0和1的患者中有33例（13.9%），232例体能状态为2至4的患者中有15例（6.4%，p<0.01）；治疗前未体重减轻的229例患者中有29例（12.2%），体重减轻的240例患者中有19例（7.9%，无显著性差异）；392例男性中有32例（8.2%），77例女性中有16例（20.7%，p<0.01）。在27例无疾病存活者中，21例在治疗开始后3.5至7年存活且无恶性肿瘤迹象。229例纳入研究后至少随访5年的患者中有10例在此期间存活且无疾病迹象。本研究证实了小细胞肺癌可能治愈，尤其是具有良好预后特征的患者。
